White crystalline powder
Myristica fragrans Houtt./the fruit of Serenoa repens
Myristic acid 1-monoglyceride/Tetradecanoic acid, 2,3-dihydroxypropyl ester/2,3-Dihydroxypropyl myristate/1-monomyristoylglycerol/rac-Glycerol 1-myristate
1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans.
424.8±25.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:589-68-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
The cytotoxicity of monomyristin (MM), a monoacylglycerol, was investigated against cervical cancer cells (HeLa) and two normal cells (Vero and endometrial epithelial cells). MM exhibited cytotoxicity specifically to HeLa cells and not against normal cells except at the highest investigated doses (> 500 μg/mL). MM was showed to increase apoptotic dead cells by intrinsic mitochondrial pathway. To overcome the poor water solubility of MM and increase its efficacy against HeLa cells, MM was encapsulated into dextran-covered polylactide (PLA) nanoparticles (NPs). NPs comprised a PLA core which encapsulated MM and a superficial layer of dextran loops which was used for conjugating a protein, transferrin (Tf), known to be overexpressed on cancer cells’ surface. Encapsulation of MM into NPs increased its cytotoxicity against HeLa cells at lower doses of MM than free MM. Additionally, the presence of conjugated Tf further increased the cytotoxicity of MM against HeLa cells as compared to non-conjugated NPs. Remarkably, both conjugated and non-conjugated MM loaded NPs were safe to normal cells (Vero and endometrial).
Copyright © 2018 Elsevier B.V. All rights reserved.
Cervical cancer; Cytotoxicity; Monomyristin; Nanoparticle; Targeting; Transferrin
Encapsulation of monomyristin into polymeric nanoparticles improved its in vitro antiproliferative activity against cervical cancer cells.
Boondireke S1, Leonard M2, Durand A2, Thanomsub Wongsatayanon B3.
2019 Apr 1
In the present work, monoacylglycerol derivatives, i.e., 1-monomyristin, 2-monomyristin, and 2-monopalmitin were successfully prepared from commercially available myristic acid and palmitic acid. The 1-monomyristin compound was prepared through a transesterification reaction between ethyl myristate and 1,2-O-isopropylidene glycerol, which was obtained from the protection of glycerol with acetone, then followed by deprotection using Amberlyst-15. On the other hand, 2-monoacylglycerol derivatives were prepared through enzymatic hydrolysis of triglycerides in the presence of Thermomyces lanuginosa lipase enzymes. The synthesized products were analyzed using fourier transform infrared (FTIR) spectrophotometer, gas or liquid chromatography-mass spectrometer (GC-MS or LC-MS), and proton and carbon nuclear magnetic resonance (¹H- and 13C-NMR) spectrometers. It was found that monomyristin showed high antibacterial and antifungal activities, while 2-monopalmitin did not show any activity at all. The 1-monomyristin compound showed higher antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also higher antifungal activity against Candida albicans compared to the positive control. Meanwhile, 2-monomyristin showed high antibacterial activity against Escherichia coli. The effect of the acyl position and carbon chains towards antibacterial and antifungal activities was discussed.
antibacterial; antifungal; monomyristin; monopalmitin; synthesis
Monomyristin and Monopalmitin Derivatives: Synthesis and Evaluation as Potential Antibacterial and Antifungal Agents.
Jumina1, Nurmala A2, Fitria A3, Pranowo D4, Sholikhah EN5, Kurniawan YS6, Kuswandi B7.
2018 Nov 29